Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis

• Market Cap: kr55.96M
• Dividend Yield: N/A
• Average Volume (3M): 102.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 127.04%
• EPS Growth: 92.31%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Devices
• EPS (TTM): -0.71
• Shares Outstanding: 20,163,593
• 10 Day Avg. Volume: 40,411
• 30 Day Avg. Volume: 102,936
• PEG Ratio: -0.23
• Price to Book (P/B): 29.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

Clinical Laserthermia Systems AB Class B faces significant challenges, primarily due to its weak financial performance characterized by consistent losses and negative cash flow. The technical indicators suggest a bearish trend with limited momentum. Additionally, the lack of profitability is reflected in the negative P/E ratio. The company needs to focus on improving its cost structure and achieving profitability to enhance its stock outlook.

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company Description

Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

How the Company Makes Money

Clinical Laserthermia Systems AB generates revenue primarily through the sale and distribution of its TRANBERG® Thermal Therapy System and related consumables. The company targets healthcare providers, hospitals, and clinics that are involved in oncological treatments as its main customer base. Revenue is also derived from providing training and support services to ensure effective implementation and usage of its technology. Additionally, CLS.B may engage in strategic partnerships and collaborations with research institutions and other medical device companies to expand its market reach and enhance product offerings, thereby contributing to its earnings.

Clinical Laserthermia Systems AB Class B Financial Statement Overview

Summary

Clinical Laserthermia Systems AB Class B is experiencing robust revenue growth but continues to face profitability challenges with consistent losses. The balance sheet is strong with low leverage, but cash flow issues persist due to negative free cash flow, highlighting a dependency on external financing. The company needs to focus on cost management to improve margins and achieve sustainable profitability.

Income Statement

The company has shown significant revenue growth from 2023 to 2024, with a growth rate of approximately 127%. However, the company continues to operate at a loss with negative net income and EBIT margins. The gross profit margin has improved but remains unsatisfactory due to high operational costs leading to negative profits.

Balance Sheet

The company has a strong equity position with a high equity ratio of around 87.5% as of 2024. The debt-to-equity ratio is very low, indicating low leverage. However, the company has consistently negative net income, impacting its return on equity, which is currently negative.

Cash Flow

The company faces challenges in generating positive cash flows with operating cash flow at zero and negative free cash flow in 2024. The financing cash flow is positive due to significant financing activities, reflecting reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
18.78M	8.27M	6.27M	2.25M	1.33M
	Gross Profit
10.42M	3.00M	-2.79M	-3.63M	876.00K
	EBIT
-54.25M	-65.93M	-67.44M	-60.68M	-52.10M
	EBITDA
-44.76M	-68.41M	-57.84M	-54.95M	-51.61M
	Net Income Common Stockholders
-47.62M	-79.79M	-70.66M	-63.62M	-57.94M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
22.51M	15.33M	10.59M	31.17M	11.87M
	Total Assets
78.56M	57.73M	49.51M	66.74M	44.40M
	Total Debt
224.00K	454.00K	30.68M	273.50K	673.50K
	Net Debt
-22.28M	-14.88M	20.23M	-1.43M	78.83K
	Total Liabilities
12.88M	14.20M	41.64M	45.55M	30.47M
	Stockholders Equity
68.72M	45.77M	9.22M	21.79M	13.93M
Cash Flow		Free Cash Flow
-63.92M	-71.95M	-71.25M	-66.73M	-55.76M
	Operating Cash Flow
0.00	-66.45M	-70.69M	-66.17M	-55.41M
	Investing Cash Flow
-7.47M	-5.50M	-886.00K	-408.00K	-508.00K
	Financing Cash Flow
71.10M	76.69M	61.84M	85.88M	62.02M

Clinical Laserthermia Systems AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Negative. The current price of 2.78 is below the 20-day moving average (MA) of 2.84, below the 50-day MA of 2.87, and below the 200-day MA of 3.92, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 45.45 is Neutral, neither overbought nor oversold. The STOCH value of 43.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLS.B.

Clinical Laserthermia Systems AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
S2M	61 Neutral	kr16.46M	―		―	96.10%	94.79%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
SPEC	41 Neutral	€217.18M	―	-20.45%	―	―	-10.85%
LXB	37 Underperform	kr99.92M	―	-51.52%	―	955.20%	47.31%
CLS.B	34 Underperform	kr55.96M	―	-79.12%	―	127.04%	92.31%
QLIFE	33 Underperform	kr36.58M	―		―	-63.52%	93.00%